MIM
HAE icon

Macroview Investment Management’s Haemonetics HAE Stock Holding History

Macroview Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32
Closed -$4K – 350
2018
Q3 		$4K Buy
+32
New +$3.31K 0.01% 178

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macroview Investment Management's HAE Position: Q4 2018 in Review

Macroview Investment Management sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 32 shares — an estimated $4K sold.

Macroview Investment Management first reported a position in HAE in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Macroview Investment Management reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Macroview Investment Management sold 32 Haemonetics shares in Q4 2018, an estimated $4K.
  • Macroview Investment Management first reported a position in Haemonetics in Q3 2018 and held it in 1 quarter.
  • Macroview Investment Management's Haemonetics position peaked at $4K in Q3 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Macroview Investment Management's 13F filing for Q4 2018, filed 7 Feb 2019.